

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

PW MEDTECH GROUP LIMITED

普 华 和 顺 集 团 公 司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1358)

OVERSEAS REGULATORY ANNOUNCEMENT RESULTS OF A SUBSIDIARY

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Sichuan Rekind Medtec., Inc. (also known as Sichuan Ruijian Medical Technology Co. Ltd.) (四川睿健醫療科技股份有限公司) (NEEQ stock code: 874652) (“**Sichuan Ruijian Medical**”), a non-wholly owned subsidiary of PW Medtech Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”), has announced its interim report and unaudited financial statements for the six months ended June 30, 2025 (the “**Reporting Period**”) on the designated disclosure platform of the National Equities Exchange and Quotation System (“**NEEQS**”) (www.neeq.com.cn). The financial statements of Sichuan Ruijian Medical have been prepared in conformity with China Accounting Standards for Business Enterprises.

A summary of the unaudited financial results of Sichuan Ruijian Medical for the Reporting Period is provided below.

INCOME STATEMENT

	For the six months ended June 30, 2025 (RMB Yuan) (Unaudited)	For the six months ended June 30, 2024 (RMB Yuan) (Unaudited)	Period-over period change
Revenue	297,880,850.00	205,894,746.66	44.68%
Profit before tax	85,425,059.86	67,004,913.25	27.49%
Income tax	15,123,484.27	10,661,644.09	41.85%
Profit for the period	70,301,575.59	56,343,269.16	24.77%
Profit attributable to the shareholders of Sichuan Ruijian Medical	72,923,582.62	56,539,538.25	28.98%

BALANCE SHEET

	As of June 30, 2025 <i>(RMB Yuan)</i> (Unaudited)	As of December 31, 2024 <i>(RMB Yuan)</i> (Audited)
Total Assets	1,035,423,433.30	938,433,223.10
Total Liabilities	88,413,337.79	77,390,272.63
Total Equity	947,010,095.51	861,042,950.47

Sichuan Ruijian Medical's revenue for the Reporting Period was RMB297,880,850.00, representing an increase of 44.68% compared to the corresponding period in 2024. This was primarily due to an increase in sales orders during the Reporting Period. Sichuan Ruijian Medical's profit for the Reporting Period was RMB70,301,575.59, representing an increase of 24.77% compared to the corresponding period in 2024. This was primarily due to the increase in gross profit, partially offset by the increase in share-based compensation expenses, staff remuneration and R&D expenses. For further details, please refer to Sichuan Ruijian Medical's unaudited financial statements for the six months ended June 30, 2025.

GENERAL INFORMATION

The Company is an exempted company incorporated under the laws of the Cayman Islands with limited liability on May 13, 2011. The principal business activity of the Company is investment holding. The Group is principally engaged in the research and development (“**R&D**”), manufacturing and sales of (i) advanced infusion set, intravenous cannula products, insulin needles etc., (ii) blood purification medical devices, and (iii) animal-derived regenerative medical biomaterial and human tissue repair alternative products in the People's Republic of China (the “**PRC**”).

Sichuan Ruijian Medical is a joint stock limited liability company established in the PRC on August 6, 2013, the shares of which are quoted on the NEEQS (NEEQ stock code: 874652). Sichuan Ruijian Medical is a medical device company, principally engaged in the R&D, manufacturing and sales of medical device for blood purification.

Shareholders of the Company should note that the above unaudited financial results pertain only to Sichuan Ruijian Medical. The unaudited financial results will be consolidated in the accounts of the Company after adjustments in accordance with all applicable Hong Kong Financial Reporting Standards. Public investors and shareholders of the Company should exercise caution when dealing in its securities.

By order of the Board
PW Medtech Group Limited
Yue'e Zhang
Chairman & Chief Executive Officer

Hong Kong, August 22, 2025

As at the date of this announcement, the Board comprises one executive Director, namely, Ms. Yue'e Zhang; two non-executive Directors, namely, Mr. Jiang Liwei and Mr. Lin Junshan; and three independent non-executive Directors, namely, Mr. Wang Xiaogang, Mr. Chen Geng and Ms. Wang Fengli.